The FOT represents the relative abundance of each GP
Peptides are derived from foods or manufactured synthetically
08, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit health care provider, today announced results from a 12-month real-world analysis of members in its GLP-1 companion program
The Cost of Weight Loss Drugs DiStefano and four other researchers conducted studies in 2024 while the shortage for semaglutide were still in place
Report Scope and Analytical Framing Concise View of Market Direction Market Size, Growth and Scenario Framing Commercial and Technical Scope How the Market Splits Into Decision-Relevant Buckets Where Demand Comes From and How It Behaves Supply Footprint, Trade and Value Capture Trade Flows and External Dependence Price Formation and Revenue Logic Who Wins and Why Where Growth and Supply Concentrate Commercial Entry and Scaling Priorities Where the Best Expansion Logic Sits Leading Players and Strategic Archetypes Detailed View of the Most Important National Markets How the Report Was Built Dominant market share in GLP-1 diabetes segment Strong competitor with dual GIP/GLP-1 agonist Early market entrant, now faces competition Markets GLP-1 in certain regions Product withdrawn in 2017-2018 Previously marketed exenatide, pipeline interest Key player in Chinese market Significant Chinese generic manufacturer Developing next-gen GLP-1/GCGR candidate GLP-1 involvement via partnerships/combinations Indirect via DPP-4 combos, pipeline interest Develops next-gen peptides, partners with Boehringer Developed long-acting GLP-1 candidate Exploring GLP-1 delivery via inhaled tech Limited direct role, potential via Sandoz generics Potential future biosimilar entrant Potential future biosimilar entrant Potential future biosimilar entrant Potential future biosimilar entrant Potential future biosimilar entrant Instant access
This definition takes pharmacokinetics into account in addition to injection frequency [13]
